Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02587598 · OUTCOME

Part 4 Only : Determination of the Efficacy of INCB053914 in Combination With the Intermediate-dose Cytarabine (I DAC) in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) Based on Objective Remission Rate (ORR)

Study of INCB053914 in Subjects With Advanced Malignancies · Source last updated 2021-12-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Approximately 2 months

What was measured

The primary efficacy endpoint of ORR in patients with AML who received INCB053914 in combination with cytarabine in Part 4 was not assessed because Part 4 was not opened for enrollment owing to this combination regimen not being tolerated in Part 3.

Analysis population: Part 4 was not opened for enrollment owing to combination regimen not being tolerated in Part 3.

Groups in this outcome

Part 4: INCB053914 50 mg BID + Cytarabine)

Combination Treatment Group A: INCB053914 50 mg BID + Cytarabine

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Part 4: INCB053914 50 mg BID + Cytarabine)0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
The primary efficacy endpoint of ORR in patients with AML who received INCB053914 in combination with cytarabine in Part 4 was not assessed because Part 4 was not opened for enrollment owing to this combination regimen not being tolerated in Part 3.
groups
  1. description
    Combination Treatment Group A: INCB053914 50 mg BID + Cytarabine
    id
    OG000
    title
    Part 4: INCB053914 50 mg BID + Cytarabine)
population Description
Part 4 was not opened for enrollment owing to combination regimen not being tolerated in Part 3.
reporting Status
POSTED
time Frame
Approximately 2 months
title
Part 4 Only : Determination of the Efficacy of INCB053914 in Combination With the Intermediate-dose Cytarabine (I DAC) in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) Based on Objective Remission Rate (ORR)
type
PRIMARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice